Biotech company Moderna expects to raise up to around 36 crore in Initial Public Offering
New Delhi: Biotech company Moderna Inc recently said it expects to raise up to $521.7 million(Rs 36,39,90,09,000) in its initial public offering, valuing the company at about $7.8 billion(Rs 5,44,20,60,00,000) at the top end of the pricing range.
The company expects its offering of 21.7 million shares to be priced between $22 and $24 per share, Moderna said in a filing.
The company, which develops drugs based on molecules known as messenger RNAs, said it intends to use a major portion of the net proceeds on drug discovery and development.
Founded in 2010, the Cambridge, Massachusetts-based company plans to list on the Nasdaq under the ticker "MRNA".
Morgan Stanley & Co LLC, Goldman Sachs & Co LLC and J.P. Morgan Securities LLC are leading an 11-member underwriting team for the IPO.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd